# Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

> **NCT01529541** · PHASE3 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 200 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Anagliptin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01529541
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01529541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01529541, "Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01529541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*